Basic Information
| LncRNA/CircRNA Name | Lnc-PDZD7 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | liver cancer tissues and cell line |
| Expression Pattern | up-regulated |
| Function Description | Lnc-PDZD7 is frequently upregulated in HCC tissues. Patients with high Lnc-PDZD7 expression had poorer prognoses and a poor response to adjuvant TACE therapy. |
| Pubmed ID | 30786928 |
| Year | 2019 |
| Title | Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. |
External Links
| Links for Lnc-PDZD7 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |